NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NeuroDerm-Parkinson's

More Like This

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

PR Newswire associated0

Neurolief Announces Breakthrough Results from Pivotal Clinical Trial of Brain Neuromodulation System for Treating Major Depressive Disorder

ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense

Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression